Kyrgyzstan Medical Device Registration State Fees: Payment Process and Budgeting 2026

1. Key takeaways

National registration of devices in Kyrgyzstan is a paid state service, and fee payment is a rigid step in the procedure: failure to pay within the period stated on the payment notice constitutes a statutory ground for refusing registration. State fees are tiered by potential use risk classes 1, 2a, 2b, and 3, with additional pricing units for extra models, in vitro diagnostic combinations, and device sets and kits. The specific amounts are governed by the payment notice issued by the competent authority. The various figures identified this cycle come from commercial consulting channels and conflict with one another; this feature therefore labels all of them as a practical estimate and treats none as a settled conclusion.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1 (procedure for national registration and expert review, including the payment step).
2. Law No. 216, Article 14: registration requires a positive expert review, and the review procedure is a paid service.
3. Law No. 216, Article 15: registration certificates are issued for an unlimited period.
4. Multilateral country research report (Japan International Cooperation Agency, November 2025): the registration fee for equipment under grant projects is 1,422 soms per model, with the payment notice issued by the competent authority after submission and paid against the notice.
5. Explanatory note to the 2026 amendment draft of the Ministry of Health of the Kyrgyz Republic: confirmation of payment is the starting point of the statutory review clock, and the draft proposes merging the completeness check and the issuance of the payment notice to shorten timelines (draft status).

Source note: the specific amounts, tiering, and payment deadlines of the state fees were not available this cycle in official source documents capable of verbatim citation. This feature states settled conclusions only at the level of structure and principle; all amounts are labeled as a practical estimate, and the payment notice issued by the competent authority prevails.

3. Expert insights

Insight 1: what is certain is the structure; what is uncertain is the numbers.

Three structural facts are certain: registration is a paid service; state fees are tiered by risk class; and failure to pay on time is a statutory ground for refusing registration. These three facts are enough to frame a budget, while the concrete figures can only be confirmed once the payment notice is issued. Our practice is to set ranges by risk class in the budget, note that the payment notice prevails, and refrain from quoting definite values.

Insight 2: payment is a procedural node, not a trailing financial settlement.

The payment notice is issued by the competent authority after the completeness check, and confirmation of payment is the starting point of the statutory clock (see Part 14 of this series). This means payment sits very early in the process: it is the key that starts the review, not the settlement after the certificate is issued. Companies should manage payment as a critical node in the project plan, not as the tail end of the finance workflow.

Insight 3: the conflict between figures from multiple sources is itself important information.

The multilateral country research report gives a grant-project figure of 1,422 soms per model, while also noting that the regular figure runs into several thousand soms per model; commercial consulting pages present a higher, tiered schedule by risk class. The gap between the two sets of figures suggests that state fees may vary significantly with project nature, risk class, and pricing unit. This also explains why deferring to the payment notice is not an evasion but the only accurate basis.

Insight 4: the variety of pricing units is the main difficulty in budgeting.

State fees are not priced only per model. Possible units also include extra models added beyond the principal model, in vitro diagnostic combinations priced by model-count bands, and device sets and kits priced by piece-count bands. When one dossier contains multiple models or bundled products, the pricing method materially changes the total cost. We recommend fixing the model and kit structure of the dossier before budgeting (see Part 23 of this series).

Insight 5: optimizing the payment step is the only time lever at project level that you control.

One of the compression measures proposed in the draft is merging the completeness check and the issuance of the payment notice (draft status). Under the current procedure, the time between issuance of the payment notice and receipt of payment is entirely in the applicant’s hands. We recommend completing internal payment approvals in advance, so that payment can be released the moment the notice arrives (see Part 14 of this series).

4. Practical recommendations

First, set budget ranges by risk class and note that the payment notice prevails. We recommend a separate budget line for state fees, ranges set by risk class, and an explicit note of the source of uncertainty, avoiding definite amounts promised externally.

Second, manage payment as a critical project node. We recommend marking two nodes in the project plan: issuance of the payment notice, and confirmed receipt of payment. The latter starts the statutory clock and should be tracked separately.

Third, complete payment approvals in advance. We recommend pre-positioning the payment workflow and authorizations at the authorized representative, so payment is released as soon as the notice arrives, cutting the waiting time in this segment.

Fourth, fix the dossier structure before estimating fees. We recommend settling the model list and the kit structure first, then estimating state fees by pricing unit, avoiding budget drift caused by structural changes.

Fifth, reserve time for possible corrections to the payment notice. If the dossier is incomplete, issuance of the payment notice is delayed, which consumes time beyond the statutory clock. We recommend aiming to submit everything complete in one pass to reduce this risk.

5. Verification checklist

• □ Confirmed that registration is a paid state service and that failure to pay on time is a statutory ground for refusal;
• □ Budget ranges set by risk class 1 / 2a / 2b / 3, with a note that the payment notice prevails;
• □ The project plan separately marks the two nodes of payment notice issuance and confirmed receipt of payment;
• □ Payment workflow and authorizations pre-positioned at the authorized representative so payment is released on receipt of the notice;
• □ Model list and kit structure of the dossier settled, and state fees estimated on that basis;
• □ Pricing units confirmed: principal models, extra models, in vitro diagnostic combinations, and device sets and kits.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance coaching, post-market surveillance and vigilance system setup, import and distribution compliance, state fee estimation, and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. It maintains a stable local cooperation network in Bishkek, Almaty, Tashkent, Moscow, and other cities, and works in Chinese, Russian, and English. For the key issues that foreign manufacturers commonly face in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection response, GRZAN provides executable solutions.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources. Any figure or timeline that cannot be verified is always labeled as a practical estimate, and experience values are never presented as legal grounds.

GRZAN provides registration and compliance support in Kyrgyzstan for medical device manufacturers, importers, and authorized representatives. For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services